Y Loriot

ALBAN (GETUG-AFU 37): a phase III, gerandomiseerde, open-label international trial of intravenous atezolizumab and in...

Annals of oncology : official journal of the European Society for Medical Oncology · 2026-01

Enfortumab vedotin plus pembrolizumab in untreated locally gevorderd or metastatic urothelial carcinoma: 2.5-year med...

Annals of oncology : official journal of the European Society for Medical Oncology · 2025-10

Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 tr...

Annals of oncology : official journal of the European Society for Medical Oncology · 2025-09

Sacituzumab govitecan in gevorderd urothelial carcinoma: TROPiCS-04, a phase III gerandomiseerde trial.

Annals of oncology : official journal of the European Society for Medical Oncology · 2025-05

Eerstelijns bij gevorderd urotheelcarcinoom: ESMO 2024 interim richtlijn update

Annals of oncology : official journal of the European Society for Medical Oncology · 2024-06

Erdafitinib bij BCG-voorbehandeld hoogrisico blaascarcinoom

Annals of oncology : official journal of the European Society for Medical Oncology · 2024-01

Erdafitinib versus pembrolizumab bij eerder behandeld FGFR-gealterd urotheelcarcinoom: THOR langetermijn

Annals of oncology : official journal of the European Society for Medical Oncology · 2024-01

Enfortumab vedotin versus chemotherapie bij urotheelcarcinoom: EV-301 24-maanden

Annals of oncology : official journal of the European Society for Medical Oncology · 2023-11

Blaascarcinoom: ESMO 2022 richtlijn

Annals of oncology : official journal of the European Society for Medical Oncology · 2022-03

Recidiefpatronen bij slechte-prognose kiemceltumoren in de GETUG 13 studie

European journal of cancer (Oxford, England : 1990) · 2017-12

Publicaties op Oncologisch.com